Patients with previously untreated , locally advanced or metastatic measurable gastric adenocarcinoma were randomly assigned to receive SIri ( irinotecan 80 mg/m ( 2 ) was administered intravenously ( i.v. ) on day 1 and 15 , while 40 mg/m ( 2 ) S-1 was orally administered twice daily for three weeks from days 1-21 followed by a two-week pause ) or SPac ( paclitaxel 50 mg/m ( 2 ) was administered i.v. on day 1 and 8 , while 40 mg/m ( 2 ) S-1 was orally administered twice daily for two weeks from day 1-14 followed by a one-week pause ) regimen .